样式: 排序: IF: - GO 导出 标记为已读
-
Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience. Am. J. Ther. (IF 4.2) Pub Date : 2024-03-08 József Attila Szász, Adriana Octaviana Dulamea, Viorelia Adelina Constantin, Dafin Fior Mureşanu, Lăcrămioara Perju Dumbravă, Cristina Tiu, Dragoş Cătălin Jianu, Mihaela Simu, Amalia Ene, Any Axelerad, Cristian Falup-Pecurariu, Mihaela Lungu, Adina Gabriela Danci, Monica Sabau, Ştefan Strilciuc, Bogdan Ovidiu Popescu
For Parkinson disease (PD) patients who have been diagnosed with advanced disease that can no longer be effectively controlled with optimized oral or transdermal medications, a range of device-aided therapies (DAT) are available, comprising either deep brain stimulation or infusion therapies providing continuous dopaminergic stimulation. Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion
-
Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder. Am. J. Ther. (IF 4.2) Pub Date : 2024-1-17 Kristine C Willett, LeDea R Bond, Amanda M Morrill, Dima Lorena, Ifteni Petru
Major depressive disorder (MDD) affects millions of people and is the leading cause of disability worldwide. Patients report decreased quality of life and ability to perform activities of daily living. It is estimated that the current standard of care, which includes pharmacologic therapy with a selective serotonin reuptake inhibitor, is effective in 40%-60%. Additional treatment options are warranted
-
Can Medication be a Factor that Can Negatively Affect the Effect of Transcranial Magnetic Stimulation in Depression? Am. J. Ther. (IF 4.2) Pub Date : 2024-1-17 Dan A Constantin, Vlad Monescu, Ionut H Cioriceanu, Florin Gabriel Leaşu, Liliana M Rogozea
This study aims to evaluate the efficacy of transcranial magnetic stimulation (TMS) in patients with depression and whether concurrent psychotropic medication use negatively affects the treatment outcome of TMS. Patients' characteristics, predictors of treatment response, the relationship between demographics, and the selection of TMS as a treatment modality were also analyzed.
-
Effectiveness of Abrocitinib in a Patient With Chronic Actinic Dermatitis. Am. J. Ther. (IF 4.2) Pub Date : 2023-11-16 Xinxing Jin,Jianjun Qiao
-
Investigation Into Potentially Inappropriate Prescribing Patterns of Loop Diuretics in a Nationally Representative Outpatient Population. Am. J. Ther. (IF 4.2) Pub Date : 2023-10-11 Steven Fosnight, Mate Michael Soric, Jacob Smearman, Emily Graves, Melvin Vazquez, Zachary Herrington, Carl Palladino, Matthew Costello, Abby Knauss
Loop diuretic therapy effectively treats edema related to heart failure, chronic kidney disease, and liver impairment; however, evidence supporting other indications is lacking. For indications such as hypertension or dependent edema or treatment of adverse events associated with other medications, the benefits likely do not outweigh the risks, putting patients at an unacceptably high risk of poor
-
Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency. Am. J. Ther. (IF 4.2) Pub Date : 2023-9-15 Josef Wills, Melissa Horenstein, Alicia Kim, Matthew A Silva, Lorena Dima
Pyruvate kinase (PK) deficiency is a rare enzyme-linked glycolytic defect resulting in mild-to-severe chronic persistent erythrocyte hemolysis. The disease is an autosomal recessive trait caused by mutations in the PK liver and red blood cell gene characterized by insufficient erythrocyte PK activity. PK deficiency is most diagnosed in persons of northern European descent and managed with packed red
-
The New Mythology of the Body and the Transformation of the Therapeutic Space. Am. J. Ther. (IF 4.2) Pub Date : 2023-9-15 Vasile Astărăstoae, Liliana M Rogozea, Ioan Aron, Doru Botezat
The history of medicine has flowed in the wake of knowledge and social perceptions about the body and corporeality. There is no idea of health without reference to the notion of body (although "health" can have other meanings, figuratively). Considering the same history, the body was the subject of numerous segregations and categorizations due to which it was and is a "social object" and a "political
-
Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am. J. Ther. (IF 4.2) Pub Date : 2023-08-29 Huzaifa Ahmad Cheema,Abraish Ali,Mirha Ali,Abia Shahid,Muhammad Saqib Ghafoor,Mohammad Ebad Ur Rehman,Ranjit Sah,Syeda Sahra,Sharjeel Ahmad
-
Oxygen Targets After Cardiac Arrest: A Meta-analysis of Randomized Controlled Trials. Am. J. Ther. (IF 4.2) Pub Date : 2023-08-17 Sahib Singh,Amit Rout,Rahul Chaudhary,Aakash Garg,Udaya S Tantry,Paul A Gurbel
BACKGROUND Optimal oxygen saturation target in patients resuscitated after cardiac arrest is unknown. Previous randomized controlled trials (RCTs) comparing restrictive oxygen therapy with liberal therapy have shown conflicting results. STUDY QUESTION We performed a meta-analysis of available RCTs to consolidate the contrasting findings regarding the oxygen targets after cardiac arrest. DATA SOURCES
-
Bed Rest After Acute Myocardial Infarction: A Century of Expert Opinions in Cecil Textbook of Medicine. Am. J. Ther. (IF 4.2) Pub Date : 2023-7-14 Peter Manu, Eleonora-Antoaneta Dinu, Liliana M Rogozea
Complete bed rest has been a component of the management of acute myocardial infarction, which was first diagnosed in the United States in 1912. The prescribed duration of bed rest has been progressively shortened in the past century.
-
Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity. Am. J. Ther. (IF 4.2) Pub Date : 2023-7-14 Timothy Nguyen, Elaine Wong, Rebecca Cope
Obesity is a major and growing public health concern. The associated cost for obesity and its related comorbidities is approximately 30% of US health care expenditures annually. As additional pharmacotherapeutic options join the market to combat obesity, it is important to understand the financial impact it may have on overall health care costs. This article explores the efficacy and pharmacoeconomics
-
Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia. Am. J. Ther. (IF 4.2) Pub Date : 2023-7-14 Jadwiga Najib, Yuliana Toderika, Lorena Dima
Insomnia is a common sleep disorder that is diagnosed primarily by patients' subjective reported symptoms. Daridorexant is a new dual orexin receptor antagonist that was recently approved by Food and Drug Administration for insomnia characterized by difficulty falling asleep and/or maintaining sleep.
-
Atezolizumab-Induced Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia. Am. J. Ther. (IF 4.2) Pub Date : 2023-07-11 Akshita Khosla,Ramandeep Singh Sandhu,Sachi Singhal,Jean-Marie Koka
-
Reimplantation of Implantable Cardiac Devices-An Ethical Controversy? Am. J. Ther. (IF 4.2) Pub Date : 2023-06-07 Vasile Astărăstoae, Liliana M Rogozea
Cardiovascular diseases are an important public health problem, the main cause of death in both men and women, with a continuous increasing prevalence and consequences upon morbidity in economic, physical, and psychological terms.The new technology have made possible the development of innovative devices, which have increased the possibility of therapeutic interventions today, extending the life of
-
Reimplantation of Implantable Cardiac Devices-An Ethical Controversy? Am. J. Ther. (IF 4.2) Pub Date : 2023-06-07 Vasile Astărăstoae,Liliana M Rogozea
BACKGROUND Cardiovascular diseases are an important public health problem, the main cause of death in both men and women, with a continuous increasing prevalence and consequences upon morbidity in economic, physical, and psychological terms.The new technology have made possible the development of innovative devices, which have increased the possibility of therapeutic interventions today, extending
-
Secukinumab-Induced Bullous Pemphigoid in a Patient With Psoriatic Arthritis. Am. J. Ther. (IF 4.2) Pub Date : 2023-06-07 Rawish Fatima,Nezam Altorok
-
Therapeutic Vaccination Is the Most Promising Intervention for Long COVID. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-26 Peter Manu
-
Unique Pharmacokinetics for Oral Tacrolimus Administration After Allogeneic Hematopoietic Stem-Cell Transplantation for AML With Shwachman-Diamond Syndrome. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-22 Yasuyuki Inoue,Yu Uemura,Shigeki Kosugi,Masatoshi Kanno,Fumiaki Sano
-
Update on Overactive Bladder Therapeutic Options Am. J. Ther. (IF 4.2) Pub Date : 2023-05-11 Caroline P. Babin, Nicole T. Catalano, David M. Yancey, Nathan Z. Pearl, Eleanor M. Koonce, Shahab Ahmadzadeh, Sahar Shekoohi, Elyse M. Cornett, Alan D. Kaye
Background: Millions of Americans are burdened by overactive bladder (OAB) syndrome and the psychogenic and economic hardships that accompany it. Several theories attempt to explain OAB as a neurogenic dysfunction, myogenic dysfunction, urothelial dysfunction, or decreased expression of a channel protein secondary to bladder outlet obstruction. Given that the etiology of OAB is a working theory, the
-
Update on Overactive Bladder Therapeutic Options. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-11 Caroline P Babin,Nicole T Catalano,David M Yancey,Nathan Z Pearl,Eleanor M Koonce,Shahab Ahmadzadeh,Sahar Shekoohi,Elyse M Cornett,Alan D Kaye
BACKGROUND Millions of Americans are burdened by overactive bladder (OAB) syndrome and the psychogenic and economic hardships that accompany it. Several theories attempt to explain OAB as a neurogenic dysfunction, myogenic dysfunction, urothelial dysfunction, or decreased expression of a channel protein secondary to bladder outlet obstruction. Given that the etiology of OAB is a working theory, the
-
Acute Ischemic Colitis Associated With Oral Phenylephrine Use: A Rare Adverse Effect of a Common Over-the-Counter Drug. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-08 Faisal Inayat,Aamir Saeed,Sobaan Taj,Sidra Kulsoom,Attiq Ur Rehman,Muhammad Kashif Amin,Zahra Akhtar,Zaka Ul Haq
-
Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Carmen-Adella Sirbu, Ruxandra Georgescu, Florentina Cristina Pleşa, Alina Paunescu, Monica Marilena Ţânţu, Alina Crenguţa Nicolae, Ionut Caloianu, Marian Mitrica
As far as 80% of people diagnosed with multiple sclerosis (MS) experience disabling symptoms in the course of the disease, such as spasticity and neuropathic pain. As first-line symptomatic therapy is associated with important adverse reactions, cannabinoids have become increasingly popular among patients with MS. This review intends to provide an overview of the evidence of the role of cannabinoids
-
Utility of Midodrine During the Recovery Phase of Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Waleed Khokher,Saffa Iftikhar,Azizullah Beran,Cameron Burmeister,Andrew Abrahamian,Ziad Abuhelwa,Saif-Eddin Malhas,Sadik Khuder,Ragheb Assaly
-
Tocilizumab and Corticosteroids Increase Risk of COVID-19-Associated Pulmonary Aspergillosis Development Among Critically Ill Patients. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Mohammed T Awad,Rajmund Michal Niwinski,Azizullah Beran,Chad Tidwell,Ayman O Soubani
-
Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Carmen-Adella Sirbu,Ruxandra Georgescu,Florentina Cristina Pleşa,Alina Paunescu,Monica Marilena Ţânţu,Alina Crenguţa Nicolae,Ionut Caloianu,Marian Mitrica
BACKGROUND As far as 80% of people diagnosed with multiple sclerosis (MS) experience disabling symptoms in the course of the disease, such as spasticity and neuropathic pain. As first-line symptomatic therapy is associated with important adverse reactions, cannabinoids have become increasingly popular among patients with MS. This review intends to provide an overview of the evidence of the role of
-
Erythema Multiforme Induced by Zonisamide and Triggered by the First Dose of COVID-19 Vaccine (Pfizer-BioNTech). Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Tsukasa Murata,Yoshitaka Nobukuni
-
Therapeutic Messianism: Belladonna for Heroin Withdrawal, Ivermectin for COVID-19 Infection. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Peter Manu
-
Fatal Myocarditis After COVID-19 Vaccination: Fourteen Autopsy-Confirmed Cases. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Peter Manu
-
Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria Am. J. Ther. (IF 4.2) Pub Date : 2023-04-27 Farhana Begum, Nida Khan, Stephanie Boisclair, Deepa A. Malieckal, David Chitty
Background: Complement-mediated HUS (CM-HUS) and paroxysmal nocturnal hemoglobinuria (PNH) are rare hematologic disorders that cause dysregulation and hyperactivation of the complement system. Historically, treatment of CM-HUS involved plasma exchange (PLEX), often with limited benefit and variable tolerance. Conversely, PNH was treated with supportive care or hemopoietic stem cell transplant. Within
-
Adjunctive Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation: A Randomized, Open-Label, Single-Center, Prospective (ADJUST-HPR) Study. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-25 Guo Long Zhe, Long Hau Yu, Dong-Hyun Lee, Moo Hyun Kim, Victor Serebruany
Cilostazol as an adjunct to dual antiplatelet therapy (DAPT) postcoronary stenting may further reduce vascular occlusion risks. The aim of this study was to assess the impact of cilostazol on high residual platelet reactivity (HRPR) in patients undergoing drug-eluting coronary stent implantation.
-
Outcome of COVID-19 mRNA Vaccination in Patients Treated With Clozapine WHO Previously Went Through SARS-COV-2 Infection. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Silvia Moga,Paula Simina Petric,Ana Aliana Miron,Petru Ifteni,Andreea Teodorescu
BACKGROUND The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had multiple consequences for the health care system, especially for patients with mental illnesses. Schizophrenia patients particularly appear to have a higher risk of complications due to coronavirus-19 (COVID-19). Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS). However
-
Outcome of COVID-19 mRNA Vaccination in Patients Treated With Clozapine WHO Previously Went Through SARS-COV-2 Infection. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-24 Silvia Moga, Paula Simina Petric, Ana Aliana Miron, Petru Ifteni, Andreea Teodorescu
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had multiple consequences for the health care system, especially for patients with mental illnesses. Schizophrenia patients particularly appear to have a higher risk of complications due to coronavirus-19 (COVID-19). Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS). However, the
-
Hypereosinophilia and Cognitive Impairment Induced by Mirtazapine. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-20 Chih-Chung Huang,Shin-Chang Kuo,Chun-Yen Chen,Yi-Wei Yeh
-
Fournier Gangrene due to Sodium-Glucose Transport Protein-2 Inhibitor Use. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-19 Brandon J Croft,Nadia Ali,Waqas Aslam
-
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection Am. J. Ther. (IF 4.2) Pub Date : 2023-04-17 Vasile Astărăstoae, Liliana M. Rogozea
Background: The COVID-19 pandemic has brought new ethical challenges to both health care professionals and the general public. Among the ethical problems amplified during this period were the making of medical decisions to quickly introduce some drugs into therapeutic practice with unproven or insufficiently proven effects (such as ivermectin), the validity of drug testing, and the allocation of limited
-
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Vasile Astărăstoae,Liliana M Rogozea
BACKGROUND The COVID-19 pandemic has brought new ethical challenges to both health care professionals and the general public. Among the ethical problems amplified during this period were the making of medical decisions to quickly introduce some drugs into therapeutic practice with unproven or insufficiently proven effects (such as ivermectin), the validity of drug testing, and the allocation of limited
-
Venous Thromboembolic Disease Provoked by Hormone-Eluting Vaginal Rings. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-13 Abdelrahman Nanah,Hamed Daw,Bahaa Abdelghaffar
-
Efficacy and Safety of Patiromer for Chronic Hyperkalemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-11 Huzaifa Ahmad Cheema,Arman Shafiee,Mohammad Mobin Teymouri Athar,Mohammad Ali Rafiei,Abia Shahid,Rehmat Ullah Awan,Abdul Mannan Khan Minhas,Mohsin Ahmad,Abdulqadir J Nashwan,Marat Fudim
-
Successful Ferric Carboxymaltose Desensitization in a Patient With Prior Reactions to Intravenous Iron Therapies. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-10 Joseph B Elmes,Donald C Moore,Mauricio Pineda-Roman
-
Rare Case of Exogenous Vasopressin-Induced Hyponatremia. Am. J. Ther. (IF 4.2) Pub Date : 2023-04-03 Jessica Liang,Zeenat Yousuf Bhat,Omer Alrawi
-
Strokes and Transient Ischemic Attacks Occurrence During Annual Dual Antiplatelet Therapy Am. J. Ther. (IF 4.2) Pub Date : 2023-03-29 Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Background: The incidence of stroke/TIA during annual dual antiplatelet therapy (ADAPT) for acute coronary syndrome (ACS) remains high. Some evidence suggests that shorter than ADAPT may diminish such risk, still providing adequate vascular protection. However, the precise timing of strokes/TIA occurrences during ADAPT is unclear but may be important for determining optimal preventive treatment duration
-
Strokes and Transient Ischemic Attacks Occurrence During Annual Dual Antiplatelet Therapy. Am. J. Ther. (IF 4.2) Pub Date : 2023-03-29 Victor L Serebruany,Jean-Francois Tanguay,Milana L Gurvich,Thomas A Marciniak,Dan Atar
BACKGROUND The incidence of stroke/TIA during annual dual antiplatelet therapy (ADAPT) for acute coronary syndrome (ACS) remains high. Some evidence suggests that shorter than ADAPT may diminish such risk, still providing adequate vascular protection. However, the precise timing of strokes/TIA occurrences during ADAPT is unclear but may be important for determining optimal preventive treatment duration
-
Severe Hyponatremia Manifesting as Status Epilepticus Caused by a Single Dose of Cyclophosphamide. Am. J. Ther. (IF 4.2) Pub Date : 2023-03-24 Abdelrahman Nanah,Seema Misbah,Hamed Daw
-
A Comparison of Variable Versus Fixed Insulin Infusion Rate on Resolution of Diabetic Ketoacidosis Am. J. Ther. (IF 4.2) Pub Date : 2023-03-03 Nathan Bohach, John M. Moorman, Brittany Cunningham, Chanda Mullen, Melissa Fowler
Background: Diabetic ketoacidosis (DKA) is a well-known, potentially fatal complication of diabetes. The American Diabetes Association hyperglycemic crises guidelines suggest the use of intravenous insulin in patients presenting with DKA, along with a recommended rate of glucose reduction of 50–75 mg/dL/h. However, no specific guidance is provided regarding how to best achieve this rate of glucose
-
Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris. Am. J. Ther. (IF 4.2) Pub Date : 2023-03-07 Hai-Zhen Hui,Ying-Jun Wang,Jia-Rong Cheng,Han Mao,Hong-Xing Guo,Qing-Chun Diao,Bing-Jun Shi
-
A Comparison of Variable Versus Fixed Insulin Infusion Rate on Resolution of Diabetic Ketoacidosis. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Nathan Bohach,John M Moorman,Brittany Cunningham,Chanda Mullen,Melissa Fowler
BACKGROUND Diabetic ketoacidosis (DKA) is a well-known, potentially fatal complication of diabetes. The American Diabetes Association hyperglycemic crises guidelines suggest the use of intravenous insulin in patients presenting with DKA, along with a recommended rate of glucose reduction of 50-75 mg/dL/h. However, no specific guidance is provided regarding how to best achieve this rate of glucose decline
-
Improvement of Refractory Chronic Actinic Dermatitis During Tofacitinib Treatment. Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Ying-Jun Wang,Hai-Zhen Hui,Jia-Rong Cheng,Han Mao,Qing-Chun Diao,Bing-Jun Shi
-
Oral Chemotherapeutic Ingestions Reported to a Poison Control Center Treated in a Health Care Facility Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Sam Ontiveros, Brenna Hogue, Allyson Kreshak, Christopher Coyne, Lee Cantrell, Alicia Minns
Background: The approach to cancer chemotherapy has changed in recent years, and there are several new oral chemotherapeutics that offer convenience to patients. These medications have toxicity, which may be particularly amplified in an overdose. Study Design: This was a retrospective review of all oral chemotherapy overdoses reported to the California Poison Control System between January 2009 and
-
The Challenge of Intermediate-Risk Pulmonary Embolism Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Spencer F. Weintraub, Joseph You, Sean Wilson, Andrew Galmer
Background: Intermediate-risk pulmonary embolism is a common disease that is associated with significant morbidity and mortality; however, a standardized treatment protocol is not well-established. Areas of Uncertainty: Treatments available for intermediate-risk pulmonary embolisms include anticoagulation, systemic thrombolytics, catheter-directed therapies, surgical embolectomy, and extracorporeal
-
Anakinra—An Interleukin-1 Receptor Antagonist for COVID-19 Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Timothy Nguyen, Lorena Dima, Kristine C. Willett
Background: Coronavirus disease (COVID-19) caused by SARS-CoV-2 virus caused a global pandemic in 2019. There are limited pharmacologic options available. The Food and Drug Administration initiated an emergency use authorization process to expedite pharmacologic agents to treat COVID-19. There are several agents available through the emergency use authorization process, ritonavir-boosted nirmatrelvir
-
Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Susan C. Villegas, Lorena Dima
Background: Atopic dermatitis (AD) is ranked as the third most prevalent skin condition with a worldwide prevalence of 2.4%. Atopic dermatitis is a common form of eczema. It develops in infancy or childhood and continues into adulthood with symptoms ranging from mild to severe. Pruritis and inflammation are the hallmark symptoms of AD. Mechanism of Action, Pharmacodynamics, and Pharmacokinetics:
-
Advances in Genetic Editing of the Human Embryo Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Vasile Astarăstoae, Beatrice Gabriela Ioan, Liliana M. Rogozea, Bianca Hanganu
Background: Genetic engineering has allowed a major development of research in this field, with specialists attempting to edit the human genome, after the successful editing of the genomes of plants and animals. However, human gene editing technologies are at the center of ethical debates around the world. Areas of Uncertainty: Ethical concerns about genetic editing of the human embryo raise several
-
Clinical Experience, Characteristics, and Performance of an Acetaminophen Absorption Test in Critically Ill Patients Am. J. Ther. (IF 4.2) Pub Date : 2023-03-01 Molly E. Droege, Abigail G. Rhoades, Christopher A. Droege, Daniel R. Mosher, Aaron M. Swomley, Neil E. Ernst, Eric W. Mueller
Background: Altered drug and nutrient absorption presents a unique challenge in critically ill patients. Performing an acetaminophen absorption test (AAT) has been used as a marker for gastric motility and upper small bowel absorption; thus, it may provide objective data regarding enteral absorptive ability in critically ill patients. Study Question: What is the clinical experience with AAT when
-
Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients. Am. J. Ther. (IF 4.2) Pub Date : 2023-05-01 Raquel Cobos-Campos,Arantza Sáez de Lafuente-Moríñigo,José Aurelio Cordero-Guevara,Cristina Bermúdez-Ampudia,Antxon Apiñaniz,Julene Argaluza,Naiara Parraza
-
Analytic Cannabis Effect on Hepatic Steatosis and Hepatic Fibrosis: A Meta-Analytic Evaluation. Am. J. Ther. (IF 4.2) Pub Date : 2023-02-28 Manesh Kumar Gangwani,Mohamad Nawras,Fnu Priyanka,Muhammad Aziz,Asif Mahmood
-
Massive Ethylene Glycol Self-Administration With Acute Kidney Injury Treated With Fomepizole Alone. Am. J. Ther. (IF 4.2) Pub Date : 2023-02-20 Duc M Dang,Michelle A Hieger
-
-
Advances in Genetic Editing of the Human Embryo. Am. J. Ther. (IF 4.2) Pub Date : 2023-02-09 Vasile Astarăstoae,Beatrice Gabriela Ioan,Liliana M Rogozea,Bianca Hanganu
BACKGROUND Genetic engineering has allowed a major development of research in this field, with specialists attempting to edit the human genome, after the successful editing of the genomes of plants and animals. However, human gene editing technologies are at the center of ethical debates around the world. AREAS OF UNCERTAINTY Ethical concerns about genetic editing of the human embryo raise several
-
Repeated Hepatitis C Virus Recurrence in a Patient With a Prognosis of Ultimate Spontaneous Clearance: Relapse or Reinfection? Am. J. Ther. (IF 4.2) Pub Date : 2023-01-18 Jinyong Wang,Di Dai,Ying Wen
-
Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Before Rasburicase Use for Tumor Lysis Syndrome. Am. J. Ther. (IF 4.2) Pub Date : 2023-01-12 Rachaita Lakra,Udhayvir Singh Grewal,Poornima Ramadas